Mitchell Chan
Direktor/Vorstandsmitglied bei AVALO THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Mitchell Chan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AVALO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.12.2021 | - |
Independent Dir/Board Member | 01.12.2021 | - | |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Direktor/Vorstandsmitglied | 11.03.2020 | - |
Karriereverlauf von Mitchell Chan
Ehemalige bekannte Positionen von Mitchell Chan
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VIELA BIO, INC. | Comptroller/Controller/Auditor | 01.06.2019 | 15.03.2021 |
Finanzdirektor/CFO | 01.06.2019 | 15.03.2021 | |
ASTRAZENECA PLC | Investor Relations Kontakt | - | - |
Ausbildung von Mitchell Chan
Rotman School of Management | Masters Business Admin |
University of Toronto | Graduate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Kanada | 3 |
Vereinigtes Königreich | 2 |
Operativ
Director/Board Member | 2 |
Comptroller/Controller/Auditor | 1 |
Director of Finance/CFO | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
Maryland Technology Council
Maryland Technology Council Miscellaneous Commercial ServicesCommercial Services The Maryland Technology Council functions as a technology trade association. The private company is based in Rockville, MD. | Commercial Services |
- Börse
- Insiders
- Mitchell Chan
- Erfahrung